NCT03447964View on ClinicalTrials.gov

Plasma Dihydroceramides Are Associated With Hepatic Steatosis in Type 1 and Type 2 Diabetes

CompletedOBSERVATIONAL
Enrollment

128

Participants

Timeline

Start Date

April 4, 2017

Primary Completion Date

September 16, 2017

Study Completion Date

September 16, 2017

Conditions
Diabetes Mellitus, Type 2Diabetes Mellitus, Type 1
Interventions
OTHER

dosing of sphingolipids

\- Measuring the concentration of many species of sphingomyelins, ceramides, dihydroceramides and sphingosine

Trial Locations (1)

75013

Groupe Hospitalier Pitié-Salpêtrière, Paris

All Listed Sponsors
lead

Groupe Hospitalier Pitie-Salpetriere

OTHER

NCT03447964 - Plasma Dihydroceramides Are Associated With Hepatic Steatosis in Type 1 and Type 2 Diabetes | Biotech Hunter | Biotech Hunter